loader2
Partner With Us NRI

Company details

214.15
227.95
172.00
369.35
6M Return -17.56%
1Y Return 4.03%
Mkt Cap.(Cr) 1,038.71
Volume 12,404
Div Yield 1.38%
OI
-
OI Chg %
-
Volume 12,404

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 245.03 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 23,081.38 -37,247.74
LAST 3M 71,111.08 -54,074.79
LAST 6M 141,746.37 -188,969.09
LAST 12M 212,995.89 -183,256.64

Information

  • About Company
  • Company Info
  • Listing Info
17.92
44.25%
80.6123
14.07%
12.62%
Description
  • Kopran was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.`92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the world`s highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran`s bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Kopran`s high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce. The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda. The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002. The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres. The company has also increased its installed capacity of Tablets & Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos). In Feb. 2001, Kopran tied up with E-Merck for co-marketing a new anti-inflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fast-moving non-steroid anti-inflammatory drugs (NSAID),has been launched in the international market. The Company also launched Cholestat (Atorvastatin - a cholesterol reducer) and further gave co-marketing rights for Atorvastatin to E-Merck (India). The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004.

Read More

Registered Address

Parijat House 1076, Dr E Moses Road Worli, Mumbai, Maharashtra, 400018

Tel : 91-22-43661111
Email : investors:kopran.com
Website : http://www.kopran.com

Registrar

Bigshare Services Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524280
NSE Code : KOPRAN
Book Closure Date (Month) : Aug
BSE Group : B
ISIN : INE082A01010

ICICIdirect Kopran Ltd FAQ

You can buy Kopran Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Kopran Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 27, 2022 04:01 PM the closing price of Kopran Ltd was ₹ 215.45.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 27, 2022 04:01 PM, the market cap of Kopran Ltd stood at ₹ 1,038.71.
The latest PE ratio of Kopran Ltd as of May 27, 2022 04:01 PM is 17.92
The latest PB ratio of Kopran Ltd as of May 27, 2022 04:01 PM is 0.37
The 52-week high of Kopran Ltd is ₹ 369.35 while the 52-week low is ₹ 172.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE